Summary of preclinical investigations in α-particle RIT of NHL
| Radionucleotide-labeled antibody | Lymphoma | Comparison with 90Y-tiuxetan-ibritumomab | Reference |
|---|---|---|---|
| 227Th-DOTA-p-benzyl-rituximab | Burkitt lymphoma (Raji) | Yes | [44] |
| 212Pb-TCMC-rituximab | Mouse lymphoma (EL4-hCD20-Luc) | No | [45] |
| 212Pb-TCMC-NNV003 (anti-CD37) | Burkitt lymphoma (Daudi), chronic lymphocytic leukemia (MEC-2) | No | [46] |
| 213Bi-(R)-2-amino-3-(4-isothiocyanatophenyl)propyl)-trans-(S,S)-cyclohexane-1,2-diamine-pentaacetic acid (SCN-CHX-A”-DTPA)-rituximab | Burkitt lymphoma (Raji) | Yes | [47] |
| 211At-1F5-B10 (anti-CD20) | Burkitt lymphoma (Ramos), mantle cell lymphoma (Granta-519) | No | [48] |
| 225Ac-DOTA-ofatumumab | Burkitt lymphoma (Raji) | No | [49] |